In addition, we found that CCL20 was elevated in the tumor residue of MDA-MB-231 xenograft tumor model in the docetaxel treatment group, in contrast to the control group, as analyzed by immunohistochemistry (IHC) staining (Fig 2E and 2F). Here, CCL20 is linked to neoplasm.